Mayer Winkler
Contributor since: 2015
Latest Articles
3 Trials That Could Alter The Diabetes Landscape Into Next Decade
Oramed Is Now The First To Show Evidence That Insulin Can Be Taken Orally
2 Peanut Allergy Plays: DBV Technologies S.A. Vs. Aimmune Therapeutics
Merck Is Improving Its Standing In A Growing Immunotherapy Subsector
3 Exposures To The Booming Japanese Stem Cell Space
Gilead Looks Set To Beat Bristol Myers Squibb In Race For Top Hepatitis C Drug
Sosei Springs Into Big Pharma's Arms With Heptares Acquisition
3 Leaders In Alzheimer's BACE Inhibition
Inside Sophiris' Lead Candidate PRX302
BioMarin Looks Attractive As Biotech Turns Around
Bionik Makes For An Intriguing Exposure To The Nascent Exoskeleton Space
Relmada Gets Big Investment - A Look At Its Pipeline
Shkreli's Antics May Be Offering A Discounted Exposure To Retrophin
Xtampza's Fate Will Reverberate Across The Pain Space
All Eyes On October 23 For Spectrum And Ligand Investors
Abuse Resistance And Oral Reformulations Bringing Life To The Opioid Space
Keep Your Eyes On Japan's And China's Dollar Reserves
The Medicare Gravy Train Into Big Pharma's Pockets Keeps Growing
Why Ardelyx Still Has Faith In Tenapanor Despite Phase II Failure
Using Upcoming Unemployment Data To Forecast The Right Allocation
Amgen Poised To Dominate A $32 Billion Biosimilar Market
AstraZeneca And Merck, Two Risk-Off Options In Immuno-Oncology
HIV, Bristol-Myers Squibb And The Future Of A Neglected Malady
After Falling Back Since Celgene Deal, Juno Could Climb Back Up Soon
Why Praluent Could Be Blockbuster For Regeneron
Greece, M2, And Dow Theory All Suggest Big Trouble Ahead For Markets
MabVax's HuMab 5B1 Toxicology Results In Context
Agios May Jump Like Bluebird On Important Data Next Month
Cancer Drug Spending Breaks Through $100B With Immunotherapy Still In Its Infancy
The Real Value In MabVax May Be Partnerships Rather Than Pipeline
GenSpera Contends In The Prodrug Space, Reaching Phase 3
Biotech Bubble? Not Really, With One Exception